Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
82
¥ million (reduction in operating loss)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending March 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥135 million+12.6%
Operating profit¥-744 million
Ordinary income¥-678 million
Net income¥-718 million
Selling, general and administrative expenses¥861 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Out-licensing activities fell short of plan; some exploratory research and platform technology activities proceeded as plannedBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue ¥135 million, gross profit ¥116 million, selling, general and administrative expenses ¥861 million, R&D expenses ¥573 million, other ¥287 million, operating loss ¥744 million, ordinary loss ¥678 million, extraordinary loss ¥37 million, net loss ¥718 million
New initiatives
- Strengthening out-licensing activities through an agreement with global consultants
- Joint research agreement with Eurus Therapeutics Co., Ltd.
- Joint research agreement with あすか製薬株式会社
- Launch of antibody screening and production services using a camel antibody library
- Technology development combining antibody-generation technology with AI drug discovery
Key KPIsA metric the company considers important as a management benchmark.
- Number of enrolled patients5 Example
- Number of clinical trial sites10 Medical institutions
- Number of antibody and reagent products90 types or more
- Number of new research-use antibody products3 Product
- Consecutive periods of growth in antibody research support revenue6 consecutive periods
- Number of employees37 People
Financial targets
Reported equity ratio of 70.1%. Target: Not disclosedNumber of stores and locations
2 locations (head office and laboratory, Nagoya laboratory). Number of additions and removals during the period: Not disclosedNumber of employees
Number of Employees37 People
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | ¥135 million (YoY +12.6%) |
| Operating profit | ¥-744 million |
| Ordinary income | ¥-678 million |
| Net income | ¥-718 million |
| Selling, general and administrative expenses | ¥861 million |
| Self-assessment against the plan | Out-licensing activities fell short of plan; some exploratory research and platform technology activities proceeded as planned |
| Breakdown of Factors Affecting the Change | Revenue ¥135 million, gross profit ¥116 million, selling, general and administrative expenses ¥861 million, R&D expenses ¥573 million, other ¥287 million, operating loss ¥744 million, ordinary loss ¥678 million, extraordinary loss ¥37 million, net loss ¥718 million |
| Key KPIs | Number of enrolled patients 5 Example, Number of clinical trial sites 10 Medical institutions, Number of antibody and reagent products 90 types or more, Number of new research-use antibody products 3 Product, Consecutive periods of growth in antibody research support revenue 6 consecutive periods, Number of employees 37 People |
| Number of stores and locations | 2 locations (head office and laboratory, Nagoya laboratory). Number of additions and removals during the period: Not disclosed |
| Number of employees | Number of Employees 37 People / Change during the period Not disclosed / Hiring plan Not disclosed |
| Financial targets | Reported equity ratio of 70.1%. Target: Not disclosed |
| New initiatives | Strengthening out-licensing activities through an agreement with global consultants, Joint research agreement with Eurus Therapeutics Co., Ltd., Joint research agreement with あすか製薬株式会社, Launch of antibody screening and production services using a camel antibody library, Technology development combining antibody-generation technology with AI drug discovery |
Items this document does not state (17)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSegment resultsUnit price and quantity metricsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Losses narrowed due to higher revenue, lower selling, general and administrative expenses and R&D expenses, and lower extraordinary losses. The company explained that R&D expenses included clinical trial costs for PPMX-T003 in aggressive NK-cell leukemia and costs related to platform technologies.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.